P888: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY

Documenti analoghi

• P888: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY
  di: F. B. Askeland, et al.
  Pubblicazione: (2022-06-01)
• DP114 | ISATUXIMAB, BORTEZOMIB, LENALIDOMIDE, DEXAMETHASONE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MYELOMA AND PLASMACYTOMAS: IMROZ SUBGROUP ANALYSIS
  di: E. Zamagni, et al.
  Pubblicazione: (2025-09-01)
• Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial
  di: Salomon Manier, et al.
  Pubblicazione: (2025-03-01)
• <i>Erratum</i> to: “Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial”
  di: Salomon Manier, et al.
  Pubblicazione: (2026-07-01)
• Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients
  di: Enrique M. Ocio, et al.
  Pubblicazione: (2023-02-01)